mRNA Cancer Vaccine Succeeds in Late-Stage Trial, Companies Say
Healthcare,MRNA,Vaccine,Cancer,Moderna,Merck
From the Right
AllSides Media Bias Rating: Lean Right
A cancer vaccine utilizing messenger ribonucleic acid (mRNA) technology prevented skin cancer from recurring in a phase 3 clinical trial, companies that make the vaccine said on Aug. 19.
The trial participants were people who underwent surgery to remove skin cancer.
The vaccine also prevented cancer from spreading in the patients, Moderna and Merck said.
Check for Bias
The AI-powered AllSides Bias Checker instantly reveals the bias of a news article. Tap the button to use.
AllSides Picks
Headline Roundup
Personalized mRNA Vaccine Reduces Risk of Melanoma Recurrence in Clinical Trials
August 19th, 2026
Headline Roundup
Prescription Drug Prices Fall 3.1% Over Past Year, Prompting Debate Over Causes
August 18th, 2026
News
Tracking Trump’s Campaign Promises
AllSides Staff
August 13th, 2026
Red Blue Translator
